Percutaneous patent foramen ovale (PFO) closure in addition to medical therapy reduces the risk of recurrent cryptogenic stroke by 60% compared with medical therapy alone, according to a meta-analysis ...
Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...
New data show zero device-related complications or atrial fibrillation, no recurrent stroke or TIA, with a cohort 40% larger than Gore and Amplatzer device studies FOUNTAIN VALLEY, Calif., Sept. 16, ...
Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a... Hookipa Pharma Inc.’s nearly $1 billion ...
, a global medical device company, today announced the presentation of additional data from its landmark RESPECT trial at the American Stroke Association's International Stroke Conference 2013 in ...
Abbott Laboratories ABT recently received FDA approval for its Amplatzer Talisman PFO Occlusion System to treat patent foramen ovale (PFO) patients at risk of recurrent ischemic stroke. The ...
Please provide your email address to receive an email when new articles are posted on . New data from the CLOSE, REDUCE and RESPECT trials demonstrated a lower rate of recurrent ischemic stroke after ...
Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
The MarketWatch News Department was not involved in the creation of this content. New data show zero device-related complications or atrial fibrillation, no recurrent stroke or TIA, with a cohort 40% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback